Dr. Martin on the Role of Transplant in Mantle Cell Lymphoma

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).

Right now, for those patients who can tolerate intensive therapy who want a very long remission duration or long treatment-free interval, high-dose cytarabine followed by autologous transplant is likely the best way to achieve that, Martin explains.

There is clearly a group of patients who should undergo transplant, but there are also many patients who can have very good outcomes without transplant. However, the difference between the 2 groups is that the latter will likely need to be administered more therapies during what would be a treatment-free interval.